ArticlePLoS pathogens2021

Luteolin as a potential host-directed immunotherapy adjunct to isoniazid treatment of tuberculosis.

Dhiraj Kumar Singh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.